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Abstract
Background Stimulation of ovulation with clomiphene citrate can cause side effects on endometrial receptivity. Formulationwith
nano-size may be an alternative therapy for women with ovulatory disorders. In this study, we investigated sustained-release
clomiphene citrate by using Phosal-based formulation (PBF) and evaluate its decreased side effect on the endometrial receptivity.
Methods In the in-vitro study, CC loaded PBF was analyzed using Zetasizer, Fourier-transform infrared spectroscopy (FTIR), and
Transmission electron microscopy (TEM). In the in-vivo study, 24 female mice were randomly divided into three groups: CC
(5 mg/kg), CC/PBF (5 mg/kg) and SS (1 ml) daily administered and injected with 5 IU HCG and mated after two days. At day 4.5,
pregnant mice were euthanized and endometrial tissue was extracted for quantitative polymerase chain reaction (Q-PCR) analysis.
Results The optimized PBF contained Phosal 50PG/glycerol in a 2:8 ratios (w/w) and the particle size of optimum formulation
was 67 ± 0.30551 nm and the release of CC fromCC-containing PBFwas slightly faster in the first 24 h; wherein, 29% of CCwas
released, and 76% of CC was released up to 120 h. The mRNA levels of leukemia inhibitory factor (LIF), leukemia inhibitory
factor receptor alpha (LIFR), HOXA10,Heparin-binding epidermal growth factor (HB-EGF), and epidermal growth factor (EGF)
were significantly upregulated andMUC1 and PGRmRNA levels were significantly downregulated in the CC-containing PBF-
treated animals compared with only CC group (P < 0.05).
Conclusion Sustained release formulation of clomiphene citrate increased its targeting efficiency and improved the impact of the
CC on implantation.
Keywords Endometrial receptivity . Clomiphene citrate . Phosal-based formulation . Sustained release
Introduction
Clomiphene citrate (CC) with the chemical name of
2-[4-[(Z)-2-chloro-1, 2-diphenylethenyl] phenoxy]-N, N-
diethylethanamine; 2-hydroxypropane-1, 2, 3-tricarboxylic acid
was used in the first line of pharmacological ovulation induction
in ovulation disorders. CC is related to a group of selective es-
trogen receptor modulators (SERMs) that can be bound to the
receptors of estrogen via agonist and antagonist functions in
cervical mucus and endometrium [1, 2]. However, CC has
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various side effects, such as anti-estrogenic action on the endo-
metrium, and CC can also potentially suppress endometrial
receptivity [3].
Implantation is associated with alteration in the expression
of genes that affect embryonic and endometrial interactions,
and any change in the expression of these genes will lead to
implantation failure and ultimately infertility [4].
Recent studies showed that the formulations for sustained-
release drug delivery systems (SRDDSs) are expected to
achieve sustained release rates, decrease the number of daily
administrations, improve compliance, and minimize the side
effects. At this point, it has been suggested that the formula-
tions, which sustain the release of CC, have been quite effective
[5]. Previous studies have revealed that phospholipids (one of
the main components of Phosal-Based Formulation (PBF)) can
be used for enhancing drug efficacy and reducing the total dose
required, quick onset of action, comfort preparation and scale-
up, reduced side effects and drug protection against hydrolysis.
Also, phospholipids protect the drugs from degradation in the
gastrointestinal tract [6]. Phosal 50PG is another compound
used in some lipid-based formulations to improve the absorp-
tion, effectiveness, decrease side effects, and therapeutic index
of the active ingredients [7, 8]. This formulation ultimately
results in the formation of transparency of a translucent water-
soluble concentrate with a particle size of approximately
100 nm [9]. To decrease the side effects of CC, we tried to
exhibit a new CC-containing PBF. Subsequently, the decreased
side effects of CC and pharmacokinetic parameters of CC-
containing PBF were examined in female mice.
Materials and methods
Materials
Clomiphene citrate (internal standard) was purchased from
Iran Hormone Pharmaceutical Co. (Tehran, Iran). Phosal 53
medium-chain triglyceride (MCT) was a kind gift from Lipoid
GmbH (Ludwigshafen, Germany). Glycerol and TRIzol were
purchased from Sigma Aldrich Merck (St. Louis, MI, USA).
Deionized water was obtained from a Milli-Q water purifica-
tion system (Millipore, Burlington, MA, USA). SYBR
Premix Ex Taq was purchased from Applied Biosystems
(Foster City, CA, USA), and cDNA synthesis kits were pur-
chased from Thermo Fisher Scientific (Waltham, MA, USA).
In-vitro studies
Preparation of PBF
A serial dilution of formulations was prepared with different
weight ratios of Phosal 50PG and glycerol in the range of 1:9
to 9:1. A consistent amount of CC was dissolved in Phosal
50PG for all formulations before glycerol was added. This
mixture was homogenized for 10 min. After the addition of
water, the mixture was vortexed and sonicated using a probe
sonicator for 10 min. The mixture was stored at room temper-
ature until the next usage. The compositions of difference
PBFs have been presented in Table 1 [10].
The optimized PBF contained Phosal 50PG/glycerol was
selected in a 2:8 ratio (w/w) for its stability test, which in-
cludes centrifuge tests, heating/cooling, and freeze/thaw cy-
cles. The protocol of these three tests was as follows: CC/PBF
solution was centrifuged at a round of 5000×g for 30 min and
no separation was performed, and if no two-phase separation
was seen, it was selected to test for heating/cooling and freeze/
thaw cycles. During the heating/cooling cycles, the samples
were incubated in 6 rounds at 4 °C and 45 °C for 48 h and their
stability was evaluated. During the freeze/thaw cycle, it was
performed three times for 48 h at −21 °C and + 25 °C, and all
instability symptoms, including phase separation, were
investigated.
Physicochemical properties of CC-containing PBF
The final formulations were diluted 50, 100, 500, and 1000
times with distilled water to assess visually any phase separa-
tion or drug precipitation immediately; this procedure was
repeated after three months. A UV–visible spectrophotometer
(Pharmacia Biotech, England) was used to determine the
transparency of the formulations. Percent transmittance of for-
mulations diluted 200 times in double distilled water was
measured at 650 nm using double distilled water as blank [10].
The mean droplet sizes and polydispersity indices (PDI) of
the formulations were measured using dynamic light scatter-
ing by a Zetasizer Nano (Malvern Panalytical, UK) at an angle
of 90° to measure the Brownian motion; in addition, the size
of the particles was determined by illuminating the particles
with a laser and analyzing the intensity of the fluctuations in
the scattered light [11]. The formulation (50 μL) was diluted
to 5 mL with double distilled water to prevent the particle
interactions and extra scattering during determination. The
dispersant viscosity was set at 0.8872 cP at 25 °C. In order
to calculate the zeta potential of formulation (50 μL), it was
diluted 100 times with double distilled water. This potential
Table 1 Composition of various Phosal-Based Formulations
Formulations
Ingredient F1 F2 F3 F4 F5 F6 F7 F8 F9
Phosal 50 PG (mg) 100 200 300 400 500 600 700 800 900
Glycerol (mg) 900 800 700 600 500 400 300 200 100
CC (mg) 5 5 5 5 5 5 5 5 5
Water (mL) 5 5 5 5 5 5 5 5 5
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was determined by Zetasizer Nano through considering the
electrophoretic mobility and afterward using the Henry eq.
A transmission electron microscopy (TEM) was used to in-
vestigate the morphological and structural features of CC-
containing PBF. Samples (50 μL) of the diluted formulations
were added to a 200-mesh film grid and dried at room tem-
perature. A TEM microscope was applied to view the stained
samples with uranyl acetate (ZEISS, Oberkochen, Germany).
The infrared spectra of CC-loaded PBF, CC and PBF were
captured by a Fourier Transform-Infrared Spectroscopy
(PerkinElmer, Waltham, MA, USA). The spectra of all the
materials were recorded at a frequency range averaged over
four runs. The powdered samples were placed on the attenu-
ated total reflectance crystal and then compressed using an
axial screw.
Evaluation of drug release from CC-containing PBF
in its release environment
The procedure for performing a standard curve on CC requires
that dilutions be made from a 20 mg stock standard solution.
A four-point curve is generally used with concentrations of
2.5, 5, 10, and 15 mg in 1 mL dimethylformamide.
Experiments were performed spectrophotometrically at
460 nm with three replicates for each concentration for inves-
tigating the in-vitro release of CC from CC-containing PBF.
Five milligrams of CC-containing PBF was added in 5 mL of
phosphate-buffered saline (PBS); pH 7.4, and the suspension
was incubated at 37 °C. The tubes were centrifuged and the
supernatants were extracted for the determination of CC,
which was evaluated by a UV–visible spectrophotometer
through a study of the absorption peak at 460 nm. Then, the
supernatants were substituted by the equal amount of fresh




Twenty-four female and 12 male mice weighing 20–50 g at
8 weeks of age were obtained from the Pasteur Institute and
maintained at 25 ± 0.5 °C, 60–80% humidity, and maintained
in a 12 h light/dark cycle. It should be noted that food and
water were also kept in the mentioned controlled condition.
Vaginal smears were evaluated every day and mice showing
just two successive estrous cycles were considered in the ex-
periments. All experiments were done following the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals (NIH Publication No. 80–23, revised 1996) and were
approved by the Research and Ethics Committee of Iran
University of Medical Sciences, Iran, (IR-IUMS.1394.94–
05–117-27,524).
Ovarian stimulation
All the female mice were divided into three groups: normal
saline solution (SS), CC-containing PBF, and CC. The dose
received was based on previous studies [12, 13]. The stage of
the estrous cycle was determined by microscopic analysis of the
predominant cell type in vaginal smears (Fig. 1). In the proestrus
step, mice have orally directed CC-containing (5 mg/kg), CC/
PBF and SS (1 ml) daily for two days. All the female mice were
injected with human chronic gonadotropin (HCG) 5 IU (Lizhu
Pharmaceutical Co., China) at 05:00 pm two days later and then
they were coupled with a sexually mature male mouse [14]. The
vaginal plugs were investigated at the next morning and this day
was called gestation day 1. Besides, the pregnant animals were
killed with ether on day 4.5, and the endometrial tissues were
collected and frozen in liquid nitrogen and stored at −80 °C for
RNA extraction. Blood serum was separated from the collected
blood by centrifugation at 4000×g for 10 min. The serum sam-
ples were stored in a deep freezer at −20 °C. The blood estradiol
(E2) concentrations were measured by the Testosterone ELISA
kit (Catalog no. ab108666, Abcam, Cambridge, UK) [15].
Reverse transcription-polymerase chain reaction
(RT-PCR) analysis
Based on materials using criteria, the whole RNA was
purificated from the endometrial samples via homogenization
in 1 mL of TRIzol Substance (Merck, USA). Technical repli-
cates were followed for all samples in triplicates. All partici-
pates were incubated with DNase I to eliminate the genomic
DNA adulteration (IPTG, MBI Fermentas GmbH, St. Leon-
Rot, Germany). In order to specify the RNA concentration
(yield and purity), the samples were analyzed spectrophoto-
metrically by the A260/A280 ratio technique. Superscript
First-Strand synthesis system (200 U/mL, Invitrogen,
Carlsbad, CA, USA) and oligo dT primers (Metabion,
Martinsried, Germany) were used to reverse-transcription of
total RNA. In each PCR cycle, a reverse transcription control
was performed using the conditions mentioned before without
superscript II enzyme. In the initial investigations, the primer
pairs were evaluated via a conventional PCR protocol
(Invitrogen), and the products run on an agarose gel and con-
fined to a single band of the expected size. As the endogenous
control, quantitative RT-PCR was applied to determine the
mRNA transcript concentrations of EGF, HOXA10, PGR,
MUC1, Colony-stimulating factor (CSF1), HBEGF, LIFR,
LIF, Fibroblast growth factor-2 (FGF2) and Vascular endo-
thelial growth factor A (VEGFA), with β-ACTIN transcript
concentrations. The applied gene-specific primers have been
detailed in Table 2. Negative controls (no cDNA) were con-
sidered for all experiments. The qPCR reactions were per-
formed based on the mentioned details formerly [16]. The
qPCR data were analyzed via the CT method [16].
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Statistical analyses
All data presented as the mean ± SEM. The statistical signifi-
cance of differences between the groups was determined using
one-way analysis of variance (ANOVA), followed by
Tukey’s post hoc test. Statistical Package for the Social
Sciences (SPSS version 16.0, SPSS Inc., Chicago, IL, USA)
was used for all data analyses. A value of P < 0.05 was
considered statistically significant.
Results
Preparation and characterization of formulation
A new formulation using Phosal 50PG, as an easy-to-
use carrier for lipophilic compounds, was prepared in
glycerol. The results of the droplet size analysis re-
vealed that the differences in the weight ratio of
Phosal 50PG and glycerol did not affect the mean glob-
ule size of the formulations considerably (Fig. 2a).
Among these ratios (w/w), F2 (Phosal/glycerol = 2:8)
was selected for the subsequent experiments. In addition
to the particle size, other factors, such as maintenance
of a suitable viscosity after diluting with a constant
amount of water (administered orally in mice), stability
against creaming and phase separation, and the presence
of an adequate amount of Phosal 50PG to solubilize the
determined dose (5 mg/kg), were considered during the
selection of the optimal formulation.
Thermodynamic stability analysis
The results of the stability experiments for the freeze-thaw
cycles, heating–cooling cycles and CC-containing PBF in-
cluded centrifugation analysis were evaluated for the selected
formulations from F2 (Table 3).
The only formula (F2 (Phosal/glycerol = 2: 8)) that
remained stable under centrifuging, freeze/thawing and
heating/cooling conditions, and was not two-phase and
showed the optimum thermodynamic stability, selected for
further experiments.
The size analysis for the first day and after the third month
of preparation was followed via the stability tests of formula-
tions (Table 4). According to the particle size analysis,
sample F2 with minimal alteration in the particle size
was considered as the optimal sample for additional
examinations. The low PDI also approved the homogeneity
of droplets.
Physiochemical characterization of CC/ PBF
Differential light scattering (DLS) analysis showed that the
CC-containing PBF had a mean hydrodynamic diameter of
Fig. 1 Cytological assessment of
vaginal smears can be used to
identify the estrous stage. Three
main cell types were detected in
vaginal smear samples: (E)
nucleated epithelial cells, (C)
cornified squamous epithelial
cells, and (L) leukocytes. The
ratio of these cell types present in
the smear can be used to identify
mice in (A) proestrus, (B) estrus,
(C) metestrus, or (D) diestrus as
described in representative results
(Scale bars = 50 μm)
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67 ± 0.30551 nm and zeta potential (mV) was in the range of
−2.2 ± 0.14, and the transmittance was in the range of 80.8 ±
0.31 (Fig. 2b). The spherical structure of CC-containing PBF
samples was obtained through TEM micrographs with the
particle size of 126–250 nm. It should be noted that this size
was reliable against DLS investigations (Fig. 2c). The conju-
gated PBF NPs with Phosal 50PG and the loaded drug were
approved by FT-IR analysis where the creation of the amide
bond following conjugation was found in the peaks at
1043,993 cm−1 in Phosal 50PG to PBF NPs evidently
(Fig. 2d). The presence of the drug in NPs has been
confirmed in CC-loaded NPs via the found peaks at
695 and 669 cm−1. It may be considered that at the concentra-
tions of 2.5–15 mg/ml the linearity of the drug response was
approved. The calibration curve was obtained by plotting the
absorbance versus the concentration data and checked for lin-
ear regression. The equation of the calibration curve for CC
obtained was Y = 0.218 + 0.024X, and the calibration curve
was found to be linear in the aforementioned concentrations
(the correlation coefficient, r2 of determination was 0.166)
(Fig. 2e). The release of CC from PBF was determined
in a PBS release medium with a pH of 7.4 at 37 °C.
The drug release was examined for 7 days. The resulting
curves showed an initial rapid release phase followed by a
slower, continuous-release phase during the next 7 days
(Fig. 2f). Releasing CC from CC-containing PBF during the
first 24, 48, 72 and 96 h was 29%, 58%, 70%, and 75%,
respectively. Afterward, a Plateau is observed in the release
pattern.
The first point when the drug release reached plateau was
96 h. The drug release was then checked for sure. The time
required for the injection of the drug, which was proestrus and
estrus, was two days; in addition, given that the drug release rate
was 58% in the next 48 h, it was actually 2.9 mg/kg, and previ-
ous studies have suggested a suitable dose for ovulation to induce
maximum implantation in the range of 2.5–3 mg/kg [17, 18].
Determination of loading efficiency of the CC
In determining the amount of drug in PBF, an UV–visible
spectrophotometer was used (model UV-1650 PC; Shimadzu
Europe, Tokyo, Japan). 5 mg of CC-containing PBFwas added
to 1 mL Dichloromethane (DCM) followed by the addition of
1 mL PBS (pH 7.4) and centrifuged at 11,200 rcf for 20 mins.
Drug loading was determined at 460 nm using the UV-visible
spectrophotometer and the obtained data was compared with
the previously established standard curve. The concentration
of CC was determined using Beer’s law (Fig. 2g).
Table 2 The sequence of the primers used in the current investigation




Mucin 1, cell surface
associated (MUC1)
Forward primer TAGCATCAAGTTCAGGTCAGGC 22 60.36 50.00 3.00 2.00
Reverse primer GACTTCACGTCAGAGGCACTAA 22 60.03 50.00 5.00 3.00
Epidermal growth
factor (EGF)
Forward primer ACTGGACGGTTTGCCTCTTT 20 59.82 50.00 3.00 0.00
Reverse primer ATTCAGGGGTTGACAGAGCAT 21 59.36 47.62 3.00 2.00
Heparin-binding EGF-like
growth factor (HBEGF)
Forward primer CCCAGAAGAGATTGAGCATCCA 22 59.83 50.00 3.00 2.00
Reverse primer ACCCGAAGAACAGCAGGATAAG 22 60.09 50.00 2.00 0.00
Fibroblast growth factor-2
(FGF2)
Forward primer GACCCACACGTCAAACTACAAC 22 59.71 50.00 4.00 0.00
Reverse primer CTGTAACACACTTAGAAGCCAGC 23 59.57 47.83 5.00 2.00
Homeobox gene 10
(HOXA10)
Forward primer TGTTTAATCAGGGAGTCCAGGC 22 60.03 50.00 6.00 2.00
Reverse primer TTTTTCAACCAGCCAGGTCAAG 22 59.57 45.45 5.00 1.00
Colony stimulating
factor (CSF1)
Forward primer GGCATCATCCTAGTCTTGCTGA 22 59.90 50.00 4.00 3.00
Reverse primer AATCCAATGTCTGAGGGTCTCG 22 59.83 50.00 3.00 2.00
Leukemia inhibitory
factor (LIF)
Forward primer TTTCCAGGTACTCACTGCACTC 22 59.96 50.00 4.00 2.00
Reverse primer TCTCAGACCAACACCCTCATTG 22 59.96 50.00 5.00 3.00
Leukemia inhibitory factor
receptor alpha (LIFR)
Forward primer TGTCTGCTGACTTCTTCACCTC 22 59.96 50.00 6.00 0.00
Reverse primer TAACACGAGTGCTACTGGTTCC 22 60.03 50.00 6.00 2.00
Progesterone receptor (PGR) Forward primer AAAACTGCCCAGCATGTCGT 20 60.82 50.00 4.00 1.00
Reverse primer CAACACCGTCAAGGGTTCTCAT 22 60.81 50.00 5.00 2.00
Vascular endothelial growth
factor A (VEGFA)
Forward primer TGCAGATTATGCGGATCAAACC 22 59.38 45.45 5.00 2.00
Reverse primer TGCATTCACATTTGTTGTGC
TGTAG
22 61.02 40.00 4.00 2.00
Actin, beta (β-actin) Forward primer CAAGATCATTGCTCCTCCTG 20 58.4 50.00 6.00 1.00
Reverse primer ATCCACATCTGCTGGAAGG 19 57.3 52.60 6.00 0.00
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The highest loading efficiency (68%) was related to
the F2 formula (Phosal / glycerol = 2: 8), which showed a
better loading capacity.
Encapsulation efficiency EEð Þ %ð Þ
¼ Amount of encapsulated clomiphen citrate mgð Þ in nanocapsule
Initial amount of clomiphen citrate mgð Þ used in the recipe
 100
Hormonal assessment
As shown in Fig. 2h, the mean serum levels of E2 were
higher in the CC-administered animals against animals
in the SS groups (43.82 ± 2.64 vs. 37.5 ± 9.69, P = 0.77).
However, the mean serum levels of E2 were not
changed significantly in the CC-containing PBF-admin-
istered animals compared to SS groups (39.02 ± 3.9 vs.
37.5 ± 9.69, P = 0.98) and the mean serum levels of E2
were higher in the CC-administered animals against an-
imals in the CC-containing PBF groups (43.82 ± 2.64
vs. 39.02 ± 3.9, P = 0.85).
Gene expression in endometrial tissues
The mean mRNA levels of LIF, LIFR, HOXA10, CSF,
HBEGF and EGF in the CC-administered group were signif-
icantly lower against SS and CC-containing PBF-adminis-
tered groups (P < 0.05). However, the mean mRNA levels of
CSF, vascular endothelial growth factor (VEGF), and FGF2
were not different significantly in the CC group compared to
the SS and CC-containing PBF groups. The mean mRNA
levels of MUC1 and PGR were significantly higher in the
CC group against SS and CC-containing PBF groups
(P < 0.05; Fig. 3, Table 5).
Fig. 2 Physiochemical characterization of CC-containing PBF: (a) the
effect of Phosal 50PG: glycerol ratio (w/w) on the mean globule size of
various CC- containing PBF formulations (F1 to F9). Data are
represented as the mean ± SEM (n = 3); (b) Size of the CC-containing
PBF was determined by DLS; (c) TEM micrograph of spherical-shaped
CC-loaded PBF (bar: 250 nm). The red arrows represent a completely
dark center and the blue arrows show the bright margin of the
nanoparticle, indicating the loaded drug and the environmental PBF; (d)
FT-IR spectrum of CC/PBF; (e) Calibration curve for the release of the
CC-loaded PBF; (f) Sustained-release phenomenon exhibited by CC-
loaded PBF in PBS with pH of 7.4 at 37 °C; (g) Determination of
loading efficiency of CC; (h) Effects of CC and CC-containing PBF on
serum reproductive hormone levels in NMRI mice. Data are expressed as
the mean ± SEM
Table 3 Thermodynamic stability test of various Phosal-Based
Formulations
An observation based on the thermodynamic stability study
Ingredient H/C Cent Freez/thaw
F1 × ✓ ✓
F2 ✓ ✓ ✓
F3 ✓ ✓ ×
F4 × ✓ ✓
F5 × ✓ ✓
F6 × ✓ ×
F7 ✓ ✓ ×
F8 ✓ ✓ ×
F9 × ✓ ×
H/C: Heating-cooling cycle; Cent: Centrifugation; Freez/Tha: Freeze–
thaw cycle. √: Passed; ×: Failed
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Discussion
Ovulation disorder is the most common cause of clomiphene
citrate use in women undergoing IVF. Clomiphene citrate is
one of the selective estrogen receptor modulator drugs
(SERMs) and acts on the estrogen receptor with both estrogen
agonist and antagonistic effects in other tissues [19].
Many studies have shown that stimulation of ovulation by
CC induces reduced endometrial receptivity, but its undesir-
able effects can lead to the reduced successful embryo implan-
tation serious complications during implantation [20].
In this research, a hypothesis that encapsulation of the clo-
miphene citrate lipid drug in PBF can reduce its effects on
non-target tissues and increase the therapeutic effect as well
as improving the pharmacological properties has been
proposed.
Our results showed that endometrial expression of LIF,
LIFR, HOXA10, HBEGF, and EGF mRNA were upregulated
and endometrial MUC1 and PGR mRNA levels were down-
regulated in the CC-containing PBF-treated animals com-
pared with the CC group. This data confirmed that CC/PBF
showed low side effects on implantation.
Given these results, the encapsulated drug in PBF and the
reduced particle size reduced damage to endometrial tissue
and improved implantation; in fact, it has been one of the
factors contributing to increasing the implant size.
The drug is loaded onto the particle surface when the nano-
particle size is higher, and, the drug is loaded into the oil core
when the particle size is smaller, for this same reason, by
measuring the particle size by DLS and zeta potential we
concluded that the lower particle size causes the higher parti-
cle stability. Also, previous studies showed that when the
particle size decreases, bioavailability and remained in blood
circulation for a long time will be increased [21]. In this study,
the optimum formula (2: 8 ratios (w/w)) was 67 ± 0.30551 nm,
which resulted in a higher blood stability rate and slower drug
release rate and this slow release of the drug reduced clomi-
phene citrate damage to the endometrial tissue. Previous stud-
ies have shown that the nano particulate drug delivery system
improves efficacy by lowering IC50 and also due to drug
protection from macrophage cells prolongs a higher blood
stability rate and slows the drug release rate [22] and also
cause the good stability during storage at room temperature
and 4 °C. It has been indicated that sometimes it is not possible
Table 4 Composition, droplet
size, and polydispersity index
(PDI) of selected clomiphene
citrate containing PBF
Ingredient Mean droplet size ± S.D. (nm) P value PDI ± S.D P value
Day 1 Month 3 Day 1 Month 3
F1 67.5 ± 0.20660 77 ± 0.40220 0.0001 0.36 ± 0.03 0.37 ± 0.05 >0.9999
F2 67 ± 0.30551 72 ± 0.50102 >0.9999 0.26 ± 0.08 0.30 ± 0.03 >0.9999
F3 67.3 ± 0.30551 73 ± 0.60221 0.001 0.36 ± 0.04 0.45 ± 0.10 0.0001
F4 68 ± 0.40441 80 ± 0.60341 0.0001 0.37 ± 0.07 0.45 ± 0.10 0.0001
F5 68 ± 0.40441 80 ± 0.60341 0.0001 0.37 ± 0.07 0.45 ± 0.10 0.0001
F6 68 ± 0.40441 82 ± 0.20551 0.0001 0.37 ± 0.07 0.45 ± 0.10 0.0001
F7 69 ± 0.50447 82 ± 0.20551 0.0001 0.39 ± 0.04 0.5 ± 0.11 0.0001
F8 69 ± 0.50447 82 ± 0.20551 0.0001 0.39 ± 0.04 0.5 ± 0.11 0.0001
F9 69 ± 0.50447 82 ± 0.20551 0.0001 0.39 ± 0.04 0.5 ± 0.11 0.0001
Fig. 3 Gene expression in endometrial tissues from pregnant mice
stimulated with CC, CC-containing PBF, and SS. The mRNA levels
were evaluated by qRT-PCR.Data are represented asmean ± SEM(n =
6each group).β-actinwas used as an internal control. (a)LIF, (b)LIFR,
(c) HOXA10, (d)MUC1, (e) PGR, (f) CSF, (g) VEGF, (h) HBEGF, (i)
EGF, (j) FGF2. *P < 0.05, ** P < 0.01, and ***P < 0.001. *the com-
parison was made between CC group vs. SS groups, † The comparison
was made between CC-containing PBF group vs. CC groups
DARU J Pharm Sci
to predict the stability of a formulation based solely on the zeta
potential values, because the electrostatic stabilization may
not be the main mechanism for the stability of these formula-
tions [8]. The presence of the solvated drugs in nano lipid
globules (<150 nm) decreased the observed side effects. The
droplet size is a very important characteristic because the rate
and extent of drug release and absorption are dependent on it
[11].
Polyols have been shown to have some remarkable advan-
tages compared with water as a continuous phase in the field
of oil-water solution. The influence of interface between oil
and polyol/water leads to reduced interfacial tension and
hence lower diameters of the oil droplets are observed com-
pared with a pure water phase. The presence of the
polyglycols in Phosal 50PG leads to a uniform formulation
and prevents phase separation [10].
These results showed that the encapsulation of the drug
into the PBF in particles of nano-size increased the targeting
efficiency and reduced the negative effects of the drug. Zeta
potential is an important factor to evaluate the stability of
colloidal systems [21]. In this study, the CC/PBF shifts to a
positive charge by the amino group. The positive charge in-
creases by the amino group and, the drug is placed on the
nanoparticle surface and slow-released.
The abnormal changes in sex hormones have been shown
in cases of underlying IVF cycle [23]. In this study, it was
observed that treatment with CC caused the increased serum
E2 levels as compared with the control group. This observa-
tion was on the same lines as the study conducted by Ertzeid
et al., who reported the increased E2 concentrations in mice
treated with CC [24]. According to these results, using Phosal
for drug delivery system may have balance the impact of CC
on the serum levels of hormones involved in implantation.
During the menstrual cycle in women, the estrogen and
progesterone hormones cause changes at the molecular level
in endometrial cells so that eventually make the endometrium
ready for blastocyst acceptance and pregnancy consolidation;
impairment of endometrial differentiation causes implantation
failure and consequently infertility. To date, no study has re-
ported the effects of clomiphene citrate on the genes of endo-
metrial receptivity in mice, such as LIF, LIFR, HOXA10, CSF,
MUC1, progesterone receptor (PGR), VEGF, EGF, FGF2,
and HBEGF. When the PGR is increased, the expression of
genes involved in implantation is reduced [25]. One of the
membranemucin glycoproteins present in the uterine epithelial
cell isMUC1.MUC1 is highly glycosylated and acts as an anti-
binding molecule on the surface of uterine epithelial cells.
Based on the role and function of MUC1 at the endometrial
level, the presence or absence of this molecule in the implan-
tation process will be important, and its overexpression inhibits
embryo attachment that this gene is affected by progesterone
and estrogen hormones, studies have shown a linear relation-
ship between MUC1, PGR and endometrial receptivity [26].
Studies have shown a linear relationship between estradiol
and PGR [27], with an increase in estradiol, PGR levels also
increase, it may negatively affect endometrial receptivity; with
an increase in PGR,MUC1 levels also increase, as well as the
endometrial receptivity decreases on the hand when some
genes like HOXA10, decrease cause endometrial defective-
ness and implantation failure [25]. By decreasing HOXA10
expression, the LIF gene expression is also decreased [28].
With increasing estradiol, VEGF gene expression decreases
and implantation rate decreases [29]. Since there is a linear
relationship between VEGF and FGF2 and EGF during im-
plantation, the expression of FGF2 and EGF decreases with
VEGF depletion [30, 31]. Another study showed that with
Table 5 Gene expression in endometrial tissues from pregnant mice stimulated with CC, CC-containing PBF, and SS





PBF (mean ± SEM)
P value
LIF 1.17 ± 0.19 0.20 ± 0.01 1.17 ± 0.19 P1 = 0.01, P2 = 0.01, P3 = 1.0
0
LIFR 0.17 ± 0.01 0.11 ± 0.0031 0.16 ± 0.010 P1 = 0.02, P2 = 0.04, P3 = 0.70
HOXA10 2.36 ± 0.15 0.52 ± 0.03 0.23 ± 0.71 P1 = 0.04, P2 = 0.05, P3 = 0.98
MUC1 0.24 ± 0.03 3.88 ± 0.08 0.26 ± 0.0004 P1 = 0.001, P2 = 0.001, P3 = 0.95
PGR 0.64 ± 0.04 2.82 ± 0.25 0.61 ± 0.26 P1 = 0.001, P2 = 0.001, P3 = 0.99
CSF 0.69 ± 0.03 0.61 ± 0.10 0.67 ± 0.17 P1 = 0.89, P2 = 0.92, P3 = 0.98
VEGF 0.69 ± 0.05 0.46 ± 0.11 0.60 ± 0.018 P1 = 0.14, P2 = 0.42, P3 = 0.66
HBEGF 1.13 ± 0.09 0.65 ± 0.031 1.06 ± 0.12 P1 = 0.03, P2 = 0.04, P3 = 0.86
EGF 1.92 ± 0.13 0.81 ± 0.080 1.89 ± 0.39 P1 = 0.04, P2 = 0.04, P3 = 0.99
FGF2 0.90 ± 0.19 0.89 ± 0.18 0.90 ± 0.01 P1 = 1.00, P2 = 1.00, P3 = 1.00
P1: The comparison was performed between CC and SS groups, P2: The comparison was performed between CC-containing PBF vs. CC groups, P3: The
comparison was performed between CC-containing PBF and SS groups. All data have been presented as the mean ± SEM. The statistical significance of
differences between the groups was determined using one-way analysis of variance (ANOVA), followed by Tukey’s post hoc test
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increased estradiol levels in women undergoing IVF, HBEGF
levels [32] and cytokines involved in implantation such as
CSF [33] decreased and also the endometrial thickness de-
creased, whereas the implantation was failed.
In this study, the mRNA levels of LIF, LIFR, HOXA10,
HBEGF, and EGF were significantly upregulated andMUC1
and PGR mRNA levels were significantly downregulated in
the CC-containing PBF-treated animals compared with only
CC group (P < 0.05).
Other studies showed that sirolimus and tumor-inhibiting
Src kinase inhibitor TG100435, which are drugs formulated
with Phosal 50PG, displayed a better overall therapeutic effect
[7]. It may be considered that phospholipids can be used in the
formulations of oral drugs as excipients in order to improve
absorption, sustain the release and decrease the side effects
[34, 35].
Foroughi et al. showed the reduced side effects of tamox-
ifen on endometrium when tamoxifen was loaded in palm oil
lipids (S154), and soy lecithin (S100) [36]. Saesoo et al.
showed the reduced side effects of cisplatin (cis–
diamminedichloroplatinum) during a cervical usage when
the cisplatin was loaded in palm oil lipids (S154), and soy
lecithin (S100) [37, 38]. These lipoids include increasing the
targeted effects of drugs and reducing their negative effects in
non-target tissues [39, 40]. Usually, phospholipids are used to
establish various carrier systems and will lead to enhance sta-
bility, solubility and successful delivery of the active pharma-
ceutical ingredients (API), including liposomes, micelles and
some solid lipid nanoparticles (SLN) [REF]. In addition,
emulsifying characteristics of phospholipids were used to as-
semble several drug delivery systems for oral and injection
interventions [10]. The reduced side effects of CC were main-
ly caused due to the presence of phospholipids in these
formulations.
CC/PBF in this study reduced the side effects of clomi-
phene citrate on endometrial tissue. In addition, the toxicity
of the drug was reduced and endometrial receptivity may be
improved by slow-release property. As a result, it showed that
the CC-encapsulated PBF in the nano-sized positively affect-
ed the implantation-related pathways compared to the CC sus-
pension. This finding suggests that the CC-containing PBF
may be a more effective ovulation stimulation drug as com-
pared to the CC suspension and has fewer side effects on
endometrial receptivity.
Conclusion
Sustained release formulation of clomiphene citrate increased
its targeting efficiency and improved the impact of the CC on
the serum levels of estradiol and expression of genes involve
implantation. A new PBF has been introduced to decrease the
side effect of clomiphene citrate on the endometrium; this
drug formulation could react better in implantation and
preventing abortion by increasing genes involved in implan-
tation. The development of PBF can provide possible alterna-
tives to conventional formulations for the oral delivery of
lipophilic compounds without any side effects on non-target
tissues.
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